Christine Sadlowski talks to Dr. Jennifer R. Brown about results from the phase 3 ALPINE study, which favored the second-generation Bruton’s tyrosine kinase inhibitor zanubrutinib over ibrutinib for relapsed/refractory CLL/SLL.